TY  - JOUR
AU  - Galldiks, N.
AU  - Langen, K.-J.
TI  - Anwendung der Aminosäure-PET in der Diagnostik und Therapie von zerebralen Gliomen (Use of amino acid PET in the diagnostic and treatment management of cerebral gliomas)
JO  - Fortschritte der Neurologie, Psychiatrie
VL  - 80
SN  - 0720-4299
CY  - Stuttgart [u.a.]
PB  - Thieme
M1  - PreJuSER-19204
SP  - 17 - 23
PY  - 2012
N1  - Record converted from VDB: 12.11.2012
AB  - Structural as well as functional imaging methods are of special importance in neurooncology. Improvements of radionuclide and magnetic resonance-based imaging modalities over the past decade have enabled clinicians to non-invasively assess the dynamics of disease-specific processes at the molecular level in patients with malignant gliomas. To date, a range of complementary imaging parameters have been established in the diagnostic work-up of patients with brain tumours. Magnetic resonance imaging (MRI) provides morphological information as well as functional information such as vascular permeability, cell density, tumour perfusion, and metabolic information by using magnetic resonance spectroscopy. The use of radiolabelled amino acids for positron emission tomography (PET) allows a better delineation of tumour margins and improves targeting of biopsy and radiotherapy, and planning surgery. In addition, amino acid imaging appears useful in distinguishing tumour recurrence from non-specific post-therapeutic scar tissue, in predicting prognosis in low-grade gliomas, and in monitoring metabolic response during treatment. Taken together, MRI and PET provide complementary information about tumour biology and activity, thereby resulting in an improved understanding of the kinetics of tumour growth and therefore allow new insights into the pathophysiology of malignant brain tumours. However, multimodal imaging studies comparing the value of amino acid PET and functional methods of MRI (e. g., perfusion and diffusion weighted imaging) are needed. From these studies, surrogate MRI and PET imaging techniques need to be derived to gain complementary structural and functional information of brain tumours that can be placed into common clinical practice which will optimise the clinical management of patients with malignant gliomas.
KW  - Amino Acids: diagnostic use
KW  - Biopsy
KW  - Brain: pathology
KW  - Brain: radionuclide imaging
KW  - Brain Neoplasms: pathology
KW  - Brain Neoplasms: radionuclide imaging
KW  - Brain Neoplasms: therapy
KW  - Combined Modality Therapy
KW  - Glioma: pathology
KW  - Glioma: radionuclide imaging
KW  - Glioma: therapy
KW  - Humans
KW  - Magnetic Resonance Imaging
KW  - Neoplasm Recurrence, Local
KW  - Neurosurgical Procedures
KW  - Patient Care Planning
KW  - Positron-Emission Tomography: methods
KW  - Prognosis
KW  - Radiopharmaceuticals: diagnostic use
KW  - Amino Acids (NLM Chemicals)
KW  - Radiopharmaceuticals (NLM Chemicals)
KW  - J (WoSType)
LB  - PUB:(DE-HGF)16
C6  - pmid:22161228
UR  - <Go to ISI:>//WOS:000299650200015
DO  - DOI:10.1055/s-0031-1281851
UR  - https://juser.fz-juelich.de/record/19204
ER  -